Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Spyre Therapeutics | Aeglea BioTherapeutics

Biotech & Life Sciences · Waltham, United States · Founded 2013 · IPO 2016 Unicorn

Develops engineered antibodies with extended half-lives to provide high-potency monotherapies and rational combinations for inflammatory bowel disease

Valuation
$5.98B
Market cap · 2026
Revenue
$886K
Latest reported FY
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

20 investors on Spyre Therapeutics | Aeglea BioTherapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
UT Horizon Fund
KBI Biopharma
Novartis Venture Fund
Lilly Ventures
Series B+ 16 investors entered at this stage
Boxer Capital
RTW Investments
Woodline Partners
Venrock Healthcare Capital Partners
Affinity Asset Advisors
Perceptive Advisors
Access Industries
Braidwell
Fairmount Funds Management
Deep Track Capital
Commodore Capital
Venrock
Polar Capital
Cormorant Asset Management
New Ground Ventures
Great Point Capital

Global footprint

Where Spyre Therapeutics | Aeglea BioTherapeutics has talent and traffic

Workforce by country
🇺🇸 United States · Waltham HQ
Book a demo for the full country breakdown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States62.7%
🇮🇳 India23.6%
🇯🇵 Japan15.5%
Top 3 markets shown

Market sentiment

What the market is saying about Spyre Therapeutics | Aeglea BioTherapeutics

An AI-synthesized read of the highest-engagement posts about Spyre Therapeutics | Aeglea BioTherapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Spyre Therapeutics | Aeglea BioTherapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles